社区

New York, NY – March 16, 2026 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful execution of two clinical training workshops in Indonesia. This initiative supports the Company's strategic expansion in Southeast Asia by providing regional healthcare providers with the practical knowledge and advanced tools needed to enhance patient care. 纽约，纽约州 – 2026年3月16日 – 微创微波消融（MWA）技术的市场领导者百德医疗投资控股有限公司（纳斯达克股票代码：BDMD）（“百德医疗”或“公司”）今日宣布，在印度尼西亚成功举办了两场临床培训研讨会。此项举措通过为地区医疗专家提供提升患者护理所需的实用知识和先进工具，进一步支持了公司在东南亚的战略扩张。 Hosted at EKA Medika Hospital and RSCM Rumah Sakit Nasional Dr. Cipto Mangunkusumo Hospital, the specialized sessions gave local physicians hands-on expe

New York, NY – March 12, 2026 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the regulatory clearance of its systems in Argentina. This milestone drives the Company's international growth, supporting a broader mission to expand patient access to highly effective, minimally invasive therapies worldwide. 纽约，2026年3月12日 —— 微创微波消融（MWA）技术的市场领导者百德医疗投资控股有限公司（纳斯达克股票代码：BDMD）（以下简称“百德医疗”或“公司”）今日宣布，其微波消融系统已顺利获得阿根廷监管部门的批准。这一重要里程碑将进一步推动公司的国际化发展，助力实现将高效微创治疗方案惠及全球更多患者的宏大愿景。 The Argentine approval strengthens Baird Medical’s growing portfolio of international certifications, which includes the United States FDA, Indonesia, Malaysia, and Vietnam. Building on this progress, t

New York, NY – March 9, 2026 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, Oregon. This engagement advances the Company’s goal to expand patient access to advanced, minimally invasive treatment options. 纽约州纽约市 – 2026年3月9日 – 微创微波消融（MWA）技术的市场领导者百德医疗投资控股有限公司（纳斯达克股票代码：BDMD）（以下简称“百德医疗”或“公司”）今日宣布，其成功在俄勒冈州波特兰市举办的2026年北美介入甲状腺病学会（NASIT）上进行了战略展示。此次参会推进了公司旨在让更多患者获得先进微创治疗方案的目标。 NASIT 2026 Specialists exploring Baird Medical’s MWA technology Baird Medical’s proprietary MWA platforms garnered significant interest during the event's thermal ablation

New York, NY – March 5, 2026 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of development for its cross-platform surgical software, officially commencing the registration process in the United States, the European Union, and China. 纽约，2026年3月5日 – 微创微波消融（MWA）技术领域的市场领导者百德医疗投资控股有限公司（纳斯达克股票代码：BDMD，以下简称“百德医疗”）今日宣布，其跨平台手术软件已成功完成开发，并正式启动在美国、欧盟及中国的注册申报程序。 Leveraging a proprietary artificial intelligence model, the system automates core clinical workflows, including anatomical mapping, dynamic treatment planning, and procedural simulations. By integrating diverse diagnostic imaging, the software assists physicians in defining precise surgical pathways and

New York, NY – March 2, 2026 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation at the 2026 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Miami, Florida. Building on successful engagements at previous NASOIE gatherings, this initiative reinforces the Company's enduring commitment to physician education and advances its strategy to expand patient access to minimally invasive therapies. 纽约，2026年3月2日 —— 微波消融（MWA）技术领域的领航者，百德医疗投资控股有限公司（Nasdaq: BDMD，以下简称“百德医疗”或“公司”）今日宣布，公司成功参加了于佛罗里达州迈阿密举行的2026年北美介入内分泌学会（NASOIE）年会。继往届会议取得丰硕成果后，此次参会再次印证了百德医疗对医师教育的长期承诺，并进一步推动了其在全球范围内扩大微创治疗普及度的战略目标。 Baird continues its engagement

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China (which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances), and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The listed company resulting from the Business Combination is Baird Medical Investment Holdings Limited ("PubCo"), and its shares and warrants will commence trading on the Nasdaq under the ticker symbols "BDMD" and "BDMDW", respectively, on October 2, 2024. 美国纽约时间，202